Genmab A/S (GMAB) to Release Quarterly Earnings on Wednesday

Genmab A/S (NASDAQ:GMAB - Get Free Report) is expected to release its earnings data on Wednesday, February 12th. Analysts expect Genmab A/S to post earnings of $0.28 per share and revenue of $884.02 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the firm earned $0.47 EPS. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Genmab A/S Stock Down 1.8 %

Shares of GMAB stock traded down $0.35 during trading hours on Friday, reaching $19.00. 1,245,703 shares of the stock traded hands, compared to its average volume of 1,682,134. Genmab A/S has a 1-year low of $18.92 and a 1-year high of $31.88. The business has a fifty day moving average price of $20.84 and a 200 day moving average price of $23.43. The firm has a market capitalization of $12.57 billion, a PE ratio of 18.45, a PEG ratio of 0.54 and a beta of 0.96.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on GMAB shares. BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and an average target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.